Familial Systemic Scleroderma
ConditionSystemic Scleroderma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Strasbourg, France
About this trial
Studying familial forms of systemic scleroderma offers several advantages:
1. To better understand the pathophysiology of a complex autoimmune disease based on "extreme" cases (familial forms); 2. To identify potential molecular markers predictive of disease progression; 3. To identify potential pathophysiological targets for developing new therapies, particularly relevant in severe and refractory forms of the disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult subjects (≥ 18 years of age)
Subjects diagnosed with systemic scleroderma by a clinician (including limited, diffuse, and sine scleroderma SSc, as well as overlap syndromes with myositis) and meeting at least the VEDOSS criteria: Raynaud's phenomenon + 1 other criterion from among: sausage fingers, antinuclear antibodies, scleroderma-specific antibodies (anti-centromere, anti-RNApolIII, anti-ScL70), capillaroscopic abnormalities
At least one first-degree relative with systemic scleroderma meeting the same criteria
Disqualifiers
None
Trial population
Adult subjects diagnosed with systemic scleroderma by a clinician
Trial design
Design model
Case-only
Time perspective
Retrospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Description of the clinical characteristics of patients with familial systemic scleroderma
The clinical presentation describes how the disease manifests in patients: the symptoms, their severity, and their progression.
Time frame
Up to 12 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov